Due to the fact that GLP-1 acting drugs such as dulaglutide, liraglutide, and semaglutide do not need dosage adjustments for patients with renal impairment, these medications are considered to be the most recommended choices for patients who have chronic kidney disease (Zheng et al
With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide
All tools are for research purposes only.
[PMID: 2493201] PubMed record related to this compound for laboratory literature review
Caraci F, Merlo S, Drago F, Caruso G, Parenti C, Sortino MA